Summary taken directly from the American College of Cardiology
Written by: Debabrata Mukherjee, MD, FACC
- Transseptal MViV in selected patients at high surgical risk was associated with a 100% technical success rate, a low complication rate, and a low mortality rate (3.3%) at 1 year.
- Based on these preliminary data, transseptal MViV may be considered for selected high-risk patients with degenerated mitral bioprosthesis who have favorable anatomy.
- Additional prospective randomized controlled studies are needed to validate these results and to assess the durability of THV performance.
Read full summary at:
Read the Editorial in JACC:
Guerrero M, Pursnani A, Narang A, Salinger M, Wang DD, Eleid M, Kodali SK, George I, Satler L, Waksman R, Meduri CU, Rajagopal V, Inglessis I, Palacios I, Reisman M, Eng MH, Russell HM, Pershad A, Fang K, Kar S, Makkar R, Saucedo J, Pearson P, Bokhary U, Kaptzan T, Lewis B, Tommaso C, Krause P, Thaden J, Oh J, Lang RM, Hahn RT, Leon MB, O’Neill WW, Feldman T, Rihal C. Prospective Evaluation of Transseptal TMVR for Failed Surgical Bioprostheses: MITRAL Trial Valve-in-Valve Arm 1-Year Outcomes. JACC Cardiovasc Interv. 2021 Apr 26;14(8):859-872. doi: 10.1016/j.jcin.2021.02.027. PMID: 33888231.Sticchi A, Reineke D, Praz F, Windecker S. Transcatheter Mitral Valve Replacement for Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Using Balloon-Expandable Transcatheter Heart Valves. JACC Cardiovasc Interv. 2021 Apr 26;14(8):873-878. doi: 10.1016/j.jcin.2021.02.034. PMID: 33888232.